 |
PDBsum entry 3as2
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Hydrolase/hydrolase inhibitor
|
PDB id
|
|
|
|
3as2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.3.2.1.14
- chitinase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Hydrolysis of the 1,4-beta-linkages of N-acetyl-D-glucosamine polymers of chitin.
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
J Biol Chem
286:24312-24323
(2011)
|
|
PubMed id:
|
|
|
|
|
| |
|
Potent family-18 chitinase inhibitors: x-ray structures, affinities, and binding mechanisms.
|
|
S.Pantoom,
I.R.Vetter,
H.Prinz,
W.Suginta.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Six novel inhibitors of Vibrio harveyi chitinase A (VhChiA), a family-18
chitinase homolog, were identified by in vitro screening of a library of
pharmacologically active compounds. Unlike the previously identified inhibitors
that mimicked the reaction intermediates, crystallographic evidence from 14
VhChiA-inhibitor complexes showed that all of the inhibitor molecules occupied
the outer part of the substrate-binding cleft at two hydrophobic areas. The
interactions at the aglycone location are well defined and tightly associated
with Trp-397 and Trp-275, whereas the interactions at the glycone location are
patchy, indicating lower affinity and a loose interaction with two consensus
residues, Trp-168 and Val-205. When Trp-275 was substituted with glycine
(W275G), the binding affinity toward all of the inhibitors dramatically
decreased, and in most structures two inhibitor molecules were found to stack
against Trp-397 at the aglycone site. Such results indicate that hydrophobic
interactions are important for binding of the newly identified inhibitors by the
chitinase. X-ray data and isothermal microcalorimetry showed that the inhibitors
occupied the active site of VhChiA in three different binding modes, including
single-site binding, independent two-site binding, and sequential two-site
binding. The inhibitory effect of dequalinium in the low nanomolar range makes
this compound an extremely attractive lead compound for plausible development of
therapeutics against human diseases involving chitinase-mediated pathologies.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
');
}
}
 |